Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339430 · ClinicalTrials.gov registry record
HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 3,500
- Enrollment target
NCT00339430: Completed study, sponsored by National Cancer Institute (NCI).
NCT00339430 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00339430 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 3,500 participants
- Enrollment target
Study Summary
Since the beginning of the HIV/AIDS epidemic, the number of women infected with HIV has rapidly increased and is continuing to climb. The Women's Interagency HIV Study is being conducted in several cities in the United States to learn more about how HIV affects women's lives and bodies. It will examine the role of HLA and killer immunoglobulin-like receptors (KIR) in HIV and related infections in HIV-positive and HIV-negative women. The study will determine the relationship between KIR and HLA genes and the following: the risk of HIV infection; HIV levels in the blood; incidence of AIDS; response to highly active antiretroviral therapy (HAART); and response to immunotherapy. Approximately 3,700 women will participate. Participants will visit the clinic every 6 months for 4 years. An HIV test will be given each time to HIV-negative women. A questionnaire will also be administered. A physical examination and gynecological examination will be given. Blood, vaginal swabs, and urine will be collected for testing. A biological impedance test will determine any changes in weight, waist-to-hip ratios, and breast and total body fat. Low CD4 counts and hospitalizations for HIV are to be self-reported to study staff.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2002-07-15 |
| Est. Completion | 2010-08-18 |
What the finished NCT00339430 record still lists
NCT00339430 is an observational study that tracks outcomes without assigning an intervention. Its 3,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00339430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00339430 about?
NCT00339430 is a clinical study titled "HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)". Since the beginning of the HIV/AIDS epidemic, the number of women infected with HIV has rapidly increased and is continuing to climb. The Women's Interagency HIV Study is being conducted in several cities in the United States to learn more about how HIV affects women's lives and bodies. It will exam...
What is the current status of trial NCT00339430?
This trial is currently completed. The enrollment target is 3,500 participants. The study started on 2002-07-15. Estimated completion is 2010-08-18.
Who is sponsoring clinical trial NCT00339430?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI